| advanced breast cancer (metastatic) | All results are NS for efficacy inferior to fulvestrant in terms of vomiting in Kaufmann, 2000 inferior to fulvestrant in terms of nausea in Kaufmann, 2000 inferior to fulvestrant in terms of hot flushes in Kaufmann, 2000 inferior to fulvestrant in terms of Objective response (assessable) in Paridaens, 2003 inferior to fulvestrant in terms of Objective response (randomised) in Paridaens, 2003 | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Chia, 2008 | vs fulvestrant | | | Clinical benefit (assessable) 1.02 [0.80; 1.31] Objective response (assessable) 1.11 [0.60; 2.05] diarrhoea 0.86 [0.37; 1.95] nausea 1.15 [0.68; 1.96] progression-free survival (reported or calculated) 1.04 [0.52; 2.07] Objective response (randomised) 1.08 [0.58; 2.01] Clinical benefit (randomised) 1.00 [0.77; 1.29] hot flushes 1.29 [0.83; 2.02] | | Kaufmann, 2000 | vs fulvestrant | | vomiting 3.72 [1.03; 13.43] nausea 1.84 [1.08; 3.15] hot flushes 2.51 [1.51; 4.17] | Clinical benefit (assessable) 0.93 [0.77; 1.13] Objective response (assessable) 0.84 [0.59; 1.19] overall survival (reported or calculated) 0.85 [0.49; 1.48] progression-free survival (reported or calculated) 0.82 [0.46; 1.45] Objective response (randomised) 0.83 [0.58; 1.18] Clinical benefit (randomised) 0.92 [0.76; 1.12] rash ∞ [NaN; ∞] | | Paridaens, 2003 | vs fulvestrant | | Objective response (assessable) 0.39 [0.21; 0.74] Objective response (randomised) 0.41 [0.22; 0.79] | Clinical benefit (assessable) 0.70 [0.49; 1.00] nausea 0.63 [0.36; 1.13] Clinical benefit (randomised) 0.74 [0.51; 1.07] arthralgia 1.74 [0.69; 4.42] hot flushes 0.79 [0.52; 1.18] |
| Trial | Treatments | Patients | Method |
|---|
| Chia, 2008 | (n=-9) vs. (n=-9) | | Sample size: -9/-9 Primary endpoint: FU duration: | | Kaufmann, 2000 | (n=-9) vs. (n=-9) | postmenopausal women with progressive advanced breast cancer who experienced failure of tamoxifen | Sample size: -9/-9 Primary endpoint: FU duration: | | Paridaens, 2003 | exemestane (n=-9) vs. tamoxifen (n=-9) | first-line hormone therapy for postmenopausal women with metastatic breast cancer | Sample size: -9/-9 Primary endpoint: FU duration: |
|
